Syngeneic Tumor Models

Accelerate Your Preclinical Immuno-oncology Research

The BioDuro Advantage

Syngeneic models are playing an important role in immunotherapy research. Due to the animals' immunocompromised status, conventional xenograft models lack relevance when it comes to studying immunotherapies. Syngeneic mouse models allow for studies on how anticancer therapeutics perform in conjunction with a functional immune system.

BioDuro's collection of validated and well-characterized syngeneic models provide an effective approach for assessing therapeutic efficacy, understanding mechanism of action and performing combination therapy studies.

Syngeneic Models

<table>
<thead>
<tr>
<th>Cancer</th>
<th>Model</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>4T1</td>
</tr>
<tr>
<td>Colon</td>
<td>CT26, MC38</td>
</tr>
<tr>
<td>Leukemia</td>
<td>C1498</td>
</tr>
<tr>
<td>Liver</td>
<td>H22, Hepa1-6</td>
</tr>
<tr>
<td>Lung</td>
<td>LLC</td>
</tr>
<tr>
<td>Melanoma</td>
<td>B16-F10</td>
</tr>
</tbody>
</table>

Validated models

In pursuit of your success.  
www.bioduro.com
Syngeneic Model: CT26 Colon Cancer

- Tumor growth inhibition curve
- Peripheral blood and tumor infiltrated lymphocytes phenotype analysis
- Serum multiplex cytokine analysis
- Histology staining
- Biomarker analysis by IHC and RT-PCR

FACS Analysis of Tumor Samples

Gating CD45+ cells from total cells

Gating Live cells from CD45+ cells

Gating CD3+ cells from CD45+ Live cells

Gating CD4+ T cells (CD4+ CD8) from CD3+ CD45+ Live cells

Gating PD-1+ cells from CD4- CD8- CD3+ CD45+ Live cells

Gating CD8+ T cells (CD4- CD8+) from CD3+ CD45+ Live cells

Immuno-phenotype Analysis of Blood and Tumor Samples

Population analysis of blood and tumor samples by FACS or RT-PCR: CD4, CD8, NK, Treg, MDSC, Macrophage, DC